Document is current
Any future updates will be listed below
-
Authors
Appidi, Tejaswini
China, Debarghya
Ștefan, George-Răzvan
Moreau, Michele
Mao, Serena
Velarde, Esteban
Toyang, Ngeh
Lowe, Henry
Rengan, Aravind Kumar
Ding, Kai
Ngwa, Wilfred
-
Funding
Funding for this research was provided by:
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
National Institutes of Health, United States (R01CA239042)
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 7 February 2025
First Online: 6 March 2025
Declarations
:
: All animal experiments were approved by the Animal Care and Use Committee of the Johns Hopkins University Animal Care and Use Committee (ACUC) for protocol #MO21M281, approved on 6 October 2021.
: All authors have consented to submit this article for publication.
: The authors NT and HL are employees of Flavocure Biotech Inc., which has commercial interest in developing Caflanone. All the other authors declare no competing interests.
